Advances in uterine leiomyoma research: The progesterone hypothesis

Environmental Health Perspectives

Volumn 108, Issue SUPPL. 5, 2000, Pages 791-793

  Rein, Mitchell S ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Women's Health Center of the North Shore   (United States)

^c NORTH SHORE MEDICAL CENTER   (United States)

Author keywords

Fibroids; Leiomyoma; Myomas; Pathogenesis; Progesterone; Uterus

Indexed keywords

ANTIGESTAGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; GONADORELIN AGONIST; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; MIFEPRISTONE; NORETHISTERONE; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; STEROID 5ALPHA REDUCTASE;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE MUTATION; GROWTH REGULATION; GROWTH STIMULATION; HISTOPATHOLOGY; HORMONAL REGULATION; HORMONE INHIBITION; HORMONE PROTEIN COMPLEX; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MITOSIS RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMATIC MUTATION; TUMOR GROWTH; UTERUS BIOPSY; UTERUS MYOMA;

EID: 0033664553     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.2307/3454308     Document Type: Article

References (29)

1. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase
2. Progesterone: A critical role in the pathogenesis of uterine myomas
3. Cytogenetic abnormalities in uterine leiomyomata
4. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in leiomyomata development
5. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata
6. Unconjugated steroids in leiomyomas and tumor-bearing myometrium
7. Estrogen biosynthesis in leiomyoma and myometrium of the uterus
8. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate
9. Regulation of estrogen (E) and progestin (p) receptors (R) in leiomyomas during the cycle and leuprolide acetate treatment
10. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata
11. Insulin-like growth factor (IGF). IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata
12. Relative overexpression of collagen type I and collagen type III messenger RNAs by uterine leiomyomas during the proliferative phase of the menstrual cycle
13. Expression of connexin-43 in human myometrium and leiomyoma
14. Relative overexpression of the parathyroid hormone-related protein gene in human leiomyomas
15. The progesterone therapy of human uterine leiomyomas
16. The effect of progestins on the mitotic activity of uterine fibromyomas
17. Mitotic activity in uterine leiomyomas during the menstrual cycle
18. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis
19. Ultrastructural study of cultured smooth muscle cells from uterine leiomyoma and myometrium under the influence of sex steroids
20. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas
21. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction
22. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up regulation by progesterone
23. Response of fibromyomas to a progestin
24. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri
25. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: A prospective, randomized, double blind, crossover trial
26. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin ″add-back″ regimens for women with leiomyomata uteri
27. Regression of uterine leiomyomata in response to the antiprogesterone RU 486
28. Restoration of estrogen-dependent progesterone receptor expression in a uterine myocyte cell line
29. 4-3-Ketosteroid 5α-oxidoreductase in human uterine leiomyoma